To assess the efficacy and safety of streptokinase in patients with acute ischemic stroke.
- Streptokinase (Streptase®)Drug
Intervention Desc: Thrombolytic agent
Double-blind, controlled trial of 310 patients at 48 centers in France and the UK.
156 patients were randomly assigned to receive streptokinase (1.5 million units over a period of one hour) and 154 received placebo. All were evaluated after 6 months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||A binary criterion combining mortality and severe disability at six months, with severe disability defined as a score of 3 or higher on the Rankin scale. The primary safety outcomes were mortality at 10 days and cerebral hemorrhage.|
|Secondary||Death, recurrent cerebrovascular events, and ischemic events.|